Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN ® (naloxone HCl) Nasal Spray as the first FDA-approved ...

Emergent BioSolutions is rated Buy after a Q3 earnings beat, CEO turnaround progress, and improved financial outlook. Read ...

GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November ...

The reduction in Emergent BioSolutions shares by BlackRock suggests a strategic shift or a reallocation within its portfolio. Holding a 3.70% position post-transaction indicates a significant but not ...

Maryland-based Emergent BioSolutions has worked its way to the front lines of the COVID-19 vaccine manufacturing field with a suite of deals to produce U.S. supply. But Emergent has more on its mind ...

What Happened: Dayal's recent move involves selling 8,552 shares of Emergent BioSolutions. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Monday.

SO, YEP YOU GOD I DO AFTER TAKING AN OATH EMERGENT BIOSOLUTIONS CEO OWNED THE PRODUCTION PROBLEMS. IN CORONAVIRUS VACCINE BACK IN MARCH AS CEO, I TAKE FULL RESPONSIBILITY FOR THAT EXECUTIVES FROM THE ...

Emergent BioSolutions recently made its Narcan naloxone nasal spray available for over-the-counter (OTC), nonprescription use starting this month. The company’s announcement that supplies of Narcan ...

As organizations accelerate their adoption of AI and cloud-native platforms, Emergent is well-positioned to help clients make confident, forward-thinking investments. Their continued focus on ...

A contractor Johnson & Johnson enlisted to make its coronavirus vaccine acknowledged Thursday that it had contaminated millions of doses, confirming reports of supply problems related to the firm’s ...